Solveig Wallberg Jonsson: None declared, Solbritt Rantapaa Dahlqvist: None declared, George Karpouzas Grant/research support from: Pfizer, Consultant for: Sanofi-Genzyme-Regeneron, Janssen, Roche-Genentech, Pfizer, Speakers bureau: BMS, Sanofi-Genzyme-Regeneron, Janssen, Roche-Genentech, Patrick Dessein: None declared, Linda Tsang: None declared, Hani El-Gabalawy: None declared, Carol Hitchon: None declared, Virginia Dr. Pascual: None declared, Irazu Contreras-Yáñez : None declared, Petros Sfrikakis: None declared, Miguel A González-Gay Grant/research support from: Prof. MA Gonzalez-Gay received grants/research supports from Abbvie, MSD, Jansen and Roche., Speakers bureau: Consultation fees/participation in company sponsored speaker's bureau from Pfizer, Lilly, Sobi, Celgene, Novartis, Roche and Sanofi., Cynthia S. Crowson: None declared, Anne Grete Semb: None declared
DOI: 10.1136/annrheumdis-2019-eular.792

SAT0110 HIGH SERUM LONG-CHAIN OMEGA-3 FATTY ACIDS ARE ASSOCIATED WITH 6-MONTH LOWER DISEASE ACTIVITY IN EARLY RA: RESULTS FROM THE ESPOIR COHORT

Johanna Sigaux¹, Camille de Brauer Buscail², Chantal Julia², Rene Marc Flipo³, Alain Cantagrel⁴, Bernard Bannwarth⁵, Francois Laporte⁶, Marie-Christophe Boissier¹, Luca Semerano¹. ¹INSERM UMR 1125, Université Paris 13, Bobigny, France; ²EREN UMR U1153 Inserm/U1125 Inra/Cnam/Univ Paris 13, Bobigny, France; ³Department of Rheumatology, Lille University Hospital, 59037, Lille, France; ⁴Centre de Rhumatologie, CHU de Toulouse, 31059, Toulouse, France; ⁵Service de rhumatologie, hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France; ⁶Département de Biochimie- Pharmacologie-Toxicologie CHU de Grenoble., Grenoble, France

Background: Dietary long-chain polyunsaturated fatty acids (PUFAs) of the n3 and n6 families are involved in immune homeostasis and can contribute to modulate inflammatory processes. Dietary intake of n3PUFA (by either supplementation or fish consumption) has been inversely associated with RA incidence in different populations. Some evidence suggests that, in subject at high risk of developing rheumatoid arthritis (RA), high erythrocyte membrane content in long-chain n3-PUFA is associated with lower ACPA prevalence and progression to RA. While long-chain n6PUFA are considered mainly proinflammatory, some, like gamma-linolenic acid (GLA), are endowed with anti-inflammatory activity, and the erythrocyte content in n6 linoleic acid was inversely associated with the development of RA in a nested-case control study. No study hitherto evaluated the longitudinal association between individual PUFA profile and disease activity in early RA.

Objectives: To characterize serum profiles of PUFA and to determine their association with baseline variables and with 6-month disease activity in a cohort of patients with early RA.

Methods: Serum PUFAs were quantified by gas chromatography-mass spectrometry (GC/MS) in 594 patients with early RA at the time of recruitment in the French Etude et Suivi des POLYarthrites Indifférenciées Récentes (ESPOIR) cohort. Principal component analysis on 19 serum fatty acids with 14 to 22 carbon atoms allowed to determine 3 orthogonal patterns of baseline serum PUFA. Pattern 1 included high proportions of short-chain fatty acids, pattern 2 was high in n3 long-chain PUFA (EPA et DHA), pattern 3 was rich in n6 long-chain fatty acids (among which, GLA had the highest concentration). Patients were stratified in tertiles according to how much the fitted into each pattern, with tertile 1 meaning lowest and tertile 3 highest fitting into the pattern. The association of PUFA patterns with baseline variables was tested in univariate analysis. The association with 6-month disease activity (with high disease activity defined as DAS28>5.1) was tested in multivariable analysis after adjustment on baseline CRP, corticosteroid and/or NSAIDs use, socioeconomic status, ACPA and RF positivity, traditional and biologic DMARDs treatment between 0 and 6 months after inclusion.

Results: In baseline univariate analysis, pattern 1 was associated with high BMI, active smoking and with non-Caucasian origin. Profile 2 was associated with higher socioeconomic status and inversely associated with DAS28 and CRP. Profile 3 was associated with ACPA positivity and higher baseline CRP. In multivariate analysis, fitting into pattern 2 and 3 was associated with lower odds of having active disease after 6 months (OR for tertile 3 vs. tertile 1: 0.49 (95% CI 0.25 to 0.97, p<0.05) for pattern 2 and 0.51 (0.28 to 0.95) for pattern 3, respectively).

Conclusion: In a cohort of early RA patients, we could identify a high serum long-chain n3PUFA profile associated with low disease activity between 0 and 6 months of follow-up in the cohort. This is consistent with a presumed immunomodulatory action of n3PUFA. Despite the baseline association with disease severity features, like ACPA positivity and

high CRP, a high serum long-chain n6PUFA profile is also associated with 6-month lower disease activity, possibly due to the presence of high concentrations of GLA in this profile.

Disclosure of Interests: Johanna Sigaux Speakers bureau: celgene, Camille de Brauer Buscail: None declared, Chantal Julia: None declared, Rene Marc Flipo: None declared, Alain Cantagrel: None declared, Bernard Bannwarth: None declared, Francois Laporte: None declared, marie-Christophe Boissier Grant/research support from: Pfizer MSD, Speakers bureau: Pfizer Lilly Biogen, Luca Semerano Grant/research support from: pfizer, Speakers bureau: pfizer, roche, msd.

DOI: 10.1136/annrheumdis-2019-eular.5911

SAT0111 RED CELL DISTRIBUTION WIDTH IS A MARKER OF EARLY RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS

Daniele Soddu¹, ^{1,2}Mattia Bellan³, Erika Zecca¹, Alessandro Croce¹, Roberta Pedrazzoli¹, Daniele Sola¹, ^{1,2}Mario Pirisi³, ^{1,2}Pierpaolo Sainaghi³. ¹AOU "Maggiore della Carità" Hospital, Internal Medicine Division, Immunorheumatology Unit, Novara, Italy; ²Università del Piemonte Orientale, Department of Translational Medicine, Novara, Italy; ³Interdisciplinary Center of Autoimmune Diseases–IRCAD, Novara, Italy

Background: Red blood cell distribution width (RDW) has recently emerged as a possible surrogate biomarker of inflammation. Its potential role as prognostic biomarker has not been evaluated yet in Rheumatoid Arthritis (RA).

Objectives: The following study aims to evaluate the potential prognostic role of RDW in the prediction of early response to methotrexate (MTX).

Methods: We performed a retrospective analysis of clinical records of patients affected by RA, according to ACR/Eular classification Criteria. The baseline RDW was recorded and correlated with disease activity scores and inflammatory markers. The response to treatment was evaluated at the 3-months follow-up visit according to Eular response criteria.

Results: We selected 88 patients (58 females, 65.9%), with a median age of 62 [52-69] years. 61 patients were positive for Rheumatoid Factor (RF) and/or anticitrullinated antibodies – anti-CCP (69.3%). The median DAS28 for Erythrocyte sedimentation rate (DAS28ESR) at the diagnosis was 4.16 [3.33-5.00] while the median RDW was 14.0 [13.1-14.9]%. The baseline RDW was directly associated to CRP ($p=0.250$; $p=0.02$), but not with ESR ($p=0.32$) or DAS28ESR ($p=0.40$).

All the patients received methotrexate (MTX) at a median dose of 10 [10-15] mg/week, 79 (89.8%) also received prednisone (median dose 5 [5-10] mg/day) and 20 hydroxychloroquine in addition to MTX. A significant trend towards a larger RDW was reported from patients with a good Eular response at three months (13.5 [13.0-14.4]%) to those with a moderate response (14.0 [13.2-14.7]%) and finally to those with a poor response (14.6 [13.6-16.0]%; $p=0.004$). At logistic regression, RDW ($p=0.02$), but not CRP or ESR ($p=0.70$ and $p=0.37$ respectively), was a predictor of a good Eular response.

Moreover, in a further logistic regression model, baseline RDW ($p=0.03$) and baseline DAS28ESR ($p=0.0009$) were the only predictors of a good Eular response at three months, while age, gender, MTX and prednisone dosage and seropositivity did not fit the model.

After the treatment RDW significantly increases (14.7 [14.0-15.7]%) and the variation of RDW from baseline is inversely related to the variation of DAS28ESR ($p=-0.263$; $p=0.02$). The increase of RDW is significantly higher in patients with a good Eular response, with a trend towards a smaller increase in case of moderate and poor response (0.95 [0.35-1.35]% vs. 0.65 [0.1-1.9]% vs. 0.2 [-0.62-0.77]%; $p=0.015$).

Conclusion: RDW is a promising predictor of early response to MTX in RA; in this context, it performs better than classical inflammatory markers. Moreover, RDW significantly increases after MTX initiation, proportionately to response to treatment, suggesting a potential role for RDW as a marker of MTX effectiveness.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.7044

SAT0112

NO DIFFERENCE IN TREATMENT CONTINUATION OF DIFFERENT BIOLOGICS IN ELDERLY PATIENTS > 70 YEARS COMPARED TO YOUNGER PATIENTS ≤ 65 YEARS

Anja Strangfeld¹, Klaus Krueger², Bernhard Manger³, Christian Kneitz⁴, Angela Zink¹, Martin Schaefer¹. ¹German Rheumatism Research Center, Epidemiology Unit, Berlin, Germany; ²Rheumatologist, Munich, Germany; ³Scientific Advisory Board, Erlangen, Germany; ⁴Rheumatologist, Schwerin, Germany

Background: Due to demographic changes an increasing number of persons reach an age above 70 years. Therefore, the adequate therapy of elderly patients with rheumatoid arthritis (RA) is an increasingly important topic.

Objectives: To compare treatment continuation of several biologic DMARDs in patients ≤ 65 with elderly patients > 70 years, stratified by onset of disease (young onset (<65 years) and late onset (≥65 years)) and by seropositivity.

Methods: The German register RABBIT is a prospective longitudinally followed cohort of RA patients enrolled with a new start of a DMARD after at least one csDMARD failure. For the current analysis patients who were enrolled with a biologic DMARD between 01/2007 and 04/2018 were included. Kaplan Meier methods were applied to analyse treatment continuation.

Results: Among the 9,819 RA patients included in the analysis, 7,972 were ≤ 65 years old and 1,847 were older than 70 years (among them 180 patients above 80 years). Among the patients ≤ 65 years, 28% received a csDMARDs and 72% a bDMARD, while among the patients above 70 years, 35% received a csDMARDs and 65% a biological. Elderly patients with a young disease onset (YORA) were more frequently women and more frequently seropositive, on average had a higher number of prior treatment failures, a worse physical function and were more likely to have joint erosions than elderly patients with late onset (LORA) (Table 1). On all bDMARD treatments investigated, elderly RA patients showed the same treatment continuation as seen in younger patients. While neither the age of the patients nor the age at disease onset changed the continuation of biologics, patients being seronegative had a significantly lower continuation with rituximab and abatacept treatment, irrespective of age (Figure 1).

Tables and Figures

Table 1. Baseline characteristics of patients, stratified by age and disease onset.

Parameter	≤ 65 years	> 70 years, LORA	> 70 years, YORA
N	7972	1009	838
Age in years	51.6 (9.5)	76.4 (3.9)	74.3 (2.9)
% female	74.7%	72.7%	79.4%
Disease duration in years	8.6 (7.8)	4.4 (3.4)	20.4 (10.4)
Number of prior therapy failures	2.1 (1.1)	1.7 (0.9)	2.5 (1.2)
ESR	27.2 (21.3)	34.6 (24.5)	33.9 (23.6)
CRP	13.4 (20)	15.3 (20.5)	16.4 (23.4)
DAS28	4.8 (1.3)	5 (1.3)	5.2 (1.3)
Number of comorbidities	1.8 (1.9)	3.4 (2.6)	3.7 (2.5)
% of patients with >3 comorbidities	26.9%	55.5%	62.4%
% of patients with no comorbidities	28.1%	4.6%	4.2%
Seropositive patients (RF/ACPA)	72.4%	69.1%	81.3%
% of full physical function	67.5 (22.4)	60.3 (24.4)	55.4 (23.4)
Glucocorticoid dose in mg/d	6 (6.2)	6.1 (4.5)	5.6 (4.4)
% of patients with joint erosions	47.9%	46.2%	76%

Where not otherwise indicated, numbers are given in the format 'mean (standard deviation)'.

Figure 1. Treatment continuity in (A) TNF inhibitors, (B) abatacept and rituximab, (C) tocilizumab

Conclusion: These results suggest that bDMARD treatment may be used for elderly patients with the same effectiveness as in younger patients.

Acknowledgement: RABBIT is supported by a joint, unconditional grant from AbbVie, Bristol-Myers Squibb, Celltrion, Hexal, Lilly, MSD Sharp & Dohme, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis and UCB.

Disclosure of Interests: Anja Strangfeld Speakers bureau: Speakers fees from Bristol-Myers Squibb, MSD, Pfizer, Roche, Klaus Krueger: None declared, Bernhard Manger: None declared, Christian Kneitz: None declared, Angela Zink Speakers bureau: Speakers fees from AbbVie, Janssen, Pfizer, Roche, Sanofi, Martin Schaefer: None declared

DOI: 10.1136/annrheumdis-2019-eular.4213

SAT0113

LIMITING FACTORS OF REACHING ACR/EULAR BOOLEAN REMISSION IN EARLY RA PATIENTS TREATED ACCORDING TO CURRENT GUIDELINES

Nina Sundlisater¹, Anna-Birgitte Aga¹, Ulf Sundin¹, Hilde Berner Hammer¹, Till Uhlig^{1,2}, Tore K. Kvien^{1,2}, Espen Haavardsholm^{1,2}, Siri Lillegården Espen Haavardsholm¹. ¹Diakonhjemmet Hospital, Oslo, Norway; ²University of Oslo, Faculty of Medicine, Oslo, Norway

Background: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission criteria have the most stringent remission definition.(1) It has been reported that patient global assessment (PGA) is the variable most commonly scored above the cut-off in patients who almost fulfill the ACR/EULAR Boolean remission criteria.(2)

Objectives: To assess which components of the ACR/EULAR Boolean criteria that most often limit attainment of remission in modern treated